Etentamig + D vs Daratumumab, Lenalidomide, & Dexamethasone in patients with newly diagnosed MM

A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Disease Types: Myelomas

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

For More Information:

https://clinicaltrials.gov/study/NCT07095452?term=NCT07095452&rank=1